home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 05/04/20

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - CytoDyn down 9% as CEO sells stock while touting COVID-19 drug

CytoDyn ( OTCQB:CYDY -8.8% ) is under early pressure on the heels of a report from STAT's Adam Feuerstein questioning management's motives behind its aggressive promotion of leronlimab for the treatment of COVID-19 patients. More news on: CytoDyn Inc., Healthcare stocks news, Stocks on...
CYDY - FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus - CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S. - CytoDyn Targets Enrollment Completion for it

VANCOUVER, Washington, May 04, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today anno...

CYDY - Repurposed Antiviral Drugs Could Set A New 'Standard Of Care' for COVID-19 Treatments Says Dr. Anthony Fauci

May 1, 2020 Palm Beach, FL – May 1, 2020 – America’s public-private sector collaboration on the global health crisis appears to have borne fruit… very quickly. The government has streamlined regulations and the public sector has responded with unheard o...

CYDY - CytoDyn: Managing My Position Following BLA Submission And COVID-19 Progress

April 27th was a big day for CytoDyn ( CYDY ) investors due to the company finally announcing they have submitted the final portion of their BLA to the FDA for leronlimab as a combination therapy with HAART for HIV. What is more, the company publicized leronlimab's branded name, Vyrologix, w...
CYDY - CytoDyn reports "strong results" with leronlimab in COVID-19

CytoDyn ( OTCQB:CYDY ) announces results from 49 U.S. COVID-19 patients who received CCR6 antagonist leronlimab under emergency use authorization. Highlights: More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

CYDY - CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries

VANCOUVER, Washington, April 30, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today an...

CYDY - CytoDyn's Drs. Pourhassan and Patterson to Present Live at Wall Street Reporter's Event to Discuss Paper Recently Submitted for Publication and Positive Results of eIND COVID-19 Patients

VANCOUVER, Washington, April 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
CYDY - Immunomedics Gets Early FDA Approval - Path To Profitability Still Treacherous

Immunonmedics (NASDAQ: IMMU) received regulatory approval from the FDA for Trodelvy (sacituzumab govitecan) for the treatment of metastatic Triple-Negative Breast Cancer (mTNBC) for patients that have had at least 2 prior therapies. The PDUFA date was June 2nd so this action is much earlier t...

CYDY - Finding The Kink In COVID-19's Armor - Preventing ARDS

The top pharmaceutical companies are trying every approach they can imagine to find the weakness in COVID-19’s armor. Pharma companies that were arch enemies are working together. Drugs that are approved for other diseases are being tested as treatments. The front runner is Gilead Scien...

CYDY - CytoDyn up 10% on completion of leronlimab application for HIV

CytoDyn ( OTCQB:CYDY +10.1% ) has completed the rolling submission of its U.S. marketing application seeking approval to use leronlimab, combined with highly active antiretroviral therapy (HAART), in treatment-experienced HIV patients, a Fast Track-tagged indication. More news on: Cyto...
Previous 10 Next 10